Pancreatic cancer: Are 'liquid biopsies' ready for prime-time?
| Autor: | Alexandra R Lewis, Mairéad G McNamara, Juan W. Valle |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
0301 basic medicine Oncology medicine.medical_specialty Stromal cell Biopsy Review 03 medical and health sciences Prostate Pancreatic cancer Internal medicine Biomarkers Tumor medicine Humans Liquid biopsy Prospective cohort study Manchester Cancer Research Centre business.industry ResearchInstitutes_Networks_Beacons/mcrc Gastroenterology Cancer DNA Neoplasm General Medicine Pancreatic cancer liquid biopsy circulating tumour cells ctDNA Neoplastic Cells Circulating medicine.disease Pancreatic Neoplasms 030104 developmental biology medicine.anatomical_structure Female CA19-9 Pancreas business |
| Zdroj: | Lewis, A, Valle, J & Mcnamara, M 2016, ' Pancreatic Cancer: are "liquid biopsies" ready for prime-time? ', World Journal of Gastroenterology, vol. 22, no. 32, pp. 7175-7185 . https://doi.org/10.3748/wjg.v22.i32.7175 |
| ISSN: | 1007-9327 |
| DOI: | 10.3748/wjg.v22.i32.7175 |
| Popis: | Pancreatic cancer is a disease that carries a poor prognosis. Accurate tissue diagnosis is required. Tumours contain a high content of stromal tissue and therefore biopsies may be inconclusive. Circulating Tumour Cells (CTCs) have been investigated as a potential “liquid biopsy” in several malignancies and have proven to be of prognostic value in breast, prostate and colorectal cancers. They have been detected in patients with localised and metastatic pancreatic cancer with sensitivities ranging from 38-100% using a variety of platforms. Circulating tumour DNA (ctDNA) has also been detected in pancreas cancer with a sensitivity ranging from 26-100% in studies across different platforms and using different genetic markers. However, there is no clear consensus on which platform is the most effective for detection, nor which genetic markers are the most useful to use. Potential roles of liquid biopsies include diagnosis, screening, guiding therapies and prognosis. The presence of CTCs or ctDNA has been shown to be of prognostic value both at diagnosis and after treatment in patients with pancreatic cancer. However, more prospective studies are required before this promising technology is ready for adoption into routine clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|